A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background The primary systemic vasculitides usually associated with autoantibodies to neutrophil cytoplasmic antigens include Wegener's granulomatosis and microscopic polyangiitis. We investigated whether exposure to cyclophosphamide in patients with generalized vasculitis could be reduced by substitution of azathioprine at remission. Methods We studied patients with a new diagnosis of generalized vasculitis and a serum creatinine concentration of 5.7 mg per deciliter (500 micromol per liter) or less. All patients received at least three months of therapy with oral cyclophosphamide and prednisolone. After remission, patients were randomly assigned to continued cyclophosphamide therapy (1.5 mg per kilogram of body weight per day) or a substitute regimen of azathioprine (2 mg per kilogram per day). Both groups continued to receive prednisolone and were followed for 18 months from study entry. Relapse was the primary end point. Results Of 155 patients studied, 144 (93 percent) entered remission and were randomly assigned to azathioprine (71 patients) or continued cyclophosphamide (73 patients). There were eight deaths (5 percent), seven of them during the first three months. Eleven relapses occurred in the azathioprine group (15.5 percent), and 10 occurred in the cyclophosphamide group (13.7 percent, P=0.65). Severe adverse events occurred in 15 patients during the induction phase (10 percent), in 8 patients in the azathioprine group during the remission phase (11 percent), and…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment includes prednisone, cyclophosphamide, or methotrexate.237,238,245”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [245]
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Nomenclature of Systemic Vasculitides
Jennette, J. C., Falk, R. J., Andrassy, K., Bacon, P. A., Churg, J., Gross, W. L., Hagen, E. C., Hoffman, G. S., Hunder, G. G., Kallenberg, C. G. M., et al. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370206 · Cited by 3,845
Self-citationWegener Granulomatosis: An Analysis of 158 Patients
Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., & Fauci, A. S. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-6-488 · Cited by 2,857
FAUCI, A. S., HAYNES, B. F., KATZ, P., & WOLFF, S. M. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-1-76 · Cited by 2,001
Short form 36 (SF36) health survey questionnaire: normative data for adults of working age.
Jenkinson, C., Coulter, A., & Wright, L. (1993) · BMJ · doi:10.1136/bmj.306.6890.1437 · Cited by 1,718
Falk, R. J., Terrell, R. S., Charles, L. A., & Jennette, J. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4115 · Cited by 1,261
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
Luqmani, R. A., BACON, P. A., Moots, R. J., Janssen, B. A., Pall, A. A., Emery, P., Savage, C. O. S., & Adu, D. (1994) · PubMed · Cited by 1,056
Self-citationSavige, J., Gillis, D., Benson, E., Davies, D., Esnault, V., Falk, R. J., Chris Hagen, E., Jayne, D., Charles Jennette, J., Paspaliaris, B., et al. (1999) · American Journal of Clinical Pathology · doi:10.1093/ajcp/111.4.507 · Cited by 884
Self-citationValidation of rheumatoid arthritis improvement criteria that include simplified joint counts
van Gestel, A. M., Haagsma, C. J., & van Riel, P. L. C. M. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199810)41:10<1845::aid-art17>3.0.co;2-k · Cited by 803
Research works printed but not linked: 10
- Jennette JC, 1989, Am J Pathol, 135, 921
- Hauer HA, 1998, Clin Exp Immunol, 112, 28
- 10.1002/(SICI)1096-9896(200002)190:3<349::AID-PATH524>3.0.CO;2-A · doi:10.1002/(sici)1096-9896(200002)190:3<349::aid-path524>3.0.co;2-a
- 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J · DOI · Paper page
- Jayne DR, 1995, QJM, 88, 127
- Luqmani RA, 1994, QJM, 87, 671
- Bacon PA, 1995, Clin Exp Rheumatol, 13, 275
- 10.1002/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q · doi:10.1002/1529-0131(199810)41:10<1835::aid-art16>3.0.co;2-q
- Szpirt WM, 1996, Int J Artif Organs, 19, 501
- 10.1002/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F · DOI · Paper page
Cited by
Items 101–200 of 999
Takayasu's arteritis--recent advances in imaging offer promise
Andrews, J., & Mason, J. C. (2007) · Rheumatology · doi:10.1093/rheumatology/kel323 · Cited by 174
Update in the Diagnosis and Management of Pulmonary Vasculitis
Frankel, S. K., Cosgrove, G. P., Fischer, A., Meehan, R. T., & Brown, K. K. (2006) · Chest · doi:10.1378/chest.129.2.452 · Cited by 172
Development of comprehensive disease assessment in systemic vasculitis
Flossmann, O., Bacon, P., de Groot, K., Jayne, D., Rasmussen, N., Seo, P., Westman, K., & Luqmani, R. (2008) · Postgraduate Medical Journal · doi:10.1136/ard.2005.051078 · Cited by 170
Self-citationPuéchal, X., Pagnoux, C., Baron, G., Quémeneur, T., Néel, A., Agard, C., Lifermann, F., Liozon, E., Ruivard, M., Godmer, P., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40205 · Cited by 169
“For SNVs without poor prognosis factors other than granulomatosis with polyangiitis (Wegener’s) (GPA), no adequately powered, randomized, controlled trial results are available to guide treatment.”
BackgroundInfluentialUpdates in ANCA-associated vasculitis
Pagnoux, C. (2019) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2015.0043 · Cited by 166
“Following induction with cyclophosphamide, patients who achieve clinical remission can be switched to a less toxic immunosuppressant for maintenance, usually after 3 months to a maximum of 6 months of cyclophosphamide (11).”
InfluentialMcAdoo, S. P., Medjeral-Thomas, N., Gopaluni, S., Tanna, A., Mansfield, N., Galliford, J., Griffith, M., Levy, J., Cairns, T. D., Jayne, D., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx378 · Cited by 165
“For case–control analysis, patients enrolled in previous EUVAS trials [Cyclophosphamide vs Azathioprine during Remission of Systemic Vasculitis (CYCAZAREM) [16], Cyclophosphamide in Systemic Vasculitis (CYCLOPS) [17] and Plasma Exchange for Renal Vasculitis (MEPEX) [18]] were identified in a ratio of 3:1 with our pati…”
MethodSelf-citationInfliximab Improves Endothelial Dysfunction in Systemic Vasculitis: A Model of Vascular Inflammation
Booth, A. D., Jayne, D. R. W., Kharbanda, R. K., McEniery, C. M., Mackenzie, I. S., Brown, J., & Wilkinson, I. B. (2004) · Circulation · doi:10.1161/01.cir.0000124720.18538.dd · Cited by 165
Self-citationNonsystemic vasculitic neuropathy: Insights from a clinical cohort
Collins, M. P., Periquet, M. I., Mendell, J. R., Sahenk, Z., Nagaraja, H. N., & Kissel, J. T. (2003) · Neurology · doi:10.1212/01.wnl.0000082715.48844.3e · Cited by 163
Guideline for Management of Vasculitis Syndrome (JCS 2008) - Digest Version -
JCS Joint Working Group (2011) · Circulation Journal · doi:10.1253/circj.cj-88-0007 · Cited by 162
ANCA-associated vasculitides—advances in pathogenesis and treatment
Chen, M., & Kallenberg, C. G. M. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.158 · Cited by 159
Microscopic polyangiitis: Clinical presentation
Villiger, P. M., & Guillevin, L. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.07.009 · Cited by 159
Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients
Charlier, C., Hénégar, C., Launay, O., Pagnoux, C., BEREZNE, A., Bienvenu, B., Cohen, P., Mouthon, L., & Guillevin, L. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.088302 · Cited by 156
Pavlakis, P. P., Alexopoulos, H., Kosmidis, M. L., Mamali, I., Moutsopoulos, H. Μ., Tzioufas, A. G., & Dalakas, M. C. (2012) · Journal of Autoimmunity · doi:10.1016/j.jaut.2012.01.003 · Cited by 152
Faurschou, M., Westman, K. W. A., Rasmussen, N., de Groot, K., Floßmann, O., Höglund, P., Jayne, D. R. W., & on behalf of the European Vasculitis Study Group (2012) · Arthritis & Rheumatism · doi:10.1002/art.34547 · Cited by 154
“Additional inclusion criteria encompassed the following: erythrocyte sedimentation rate 45 mm/hour and/or C-reactive protein level 2 times the upper limit of normal, or ANCA positivity, or a nonrenal biopsy showing alterations compatible with GPA or MPA.”
InfluentialSelf-citationHeijl, C., Harper, L., Floßmann, O., Stücker, I., Scott, D., Watts, R. A., Höglund, P., Westman, K. W. A., & Mahr, A. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.145250 · Cited by 154
Self-citationRobson, J. C., Doll, H., Suppiah, R., Floßmann, O., Harper, L., Höglund, P., Jayne, D. R. W., Mahr, A., Westman, K. W. A., & Luqmani, R. A. (2014) · Lara D. Veeken · doi:10.1093/rheumatology/keu366 · Cited by 154
Self-citationClinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides
Solans, R., Fraile, G., Rodríguez‐Carballeira, M., Caminal‐Montero, L., Castillo, M. J., Martínez‐Valle, F., Sáez, L., Blanco, J. J. R., Solanich, X., Oristrell, J., et al. (2017) · Medicine · doi:10.1097/md.0000000000006083 · Cited by 154
New pathophysiological insights and treatment of ANCA-associated vasculitis
Wilde, B., van Paassen, P., Witzke, O., & Tervaert, J. W. C. (2010) · Kidney International · doi:10.1038/ki.2010.472 · Cited by 157
Self-citationRenal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis
Sinico, R. A., Toma, L. D., & Radice, A. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.08.006 · Cited by 153
“7 mg/dl) should be treated with prednisone and cyclophosphamide for 3– 6 months until remission is reached [43].”
BackgroundLangford, C. A., Monach, P. A., Specks, U., Seo, P., Cuthbertson, D. D., McAlear, C. A., Ytterberg, S. R., Hoffman, G. S., Krischer, J. P., & Merkel, P. A. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204164 · Cited by 150
Alberici, F., Smith, R., Jones, R. B., Roberts, D. M., Willcocks, L. C., Chaudhry, A., Smith, K. G. C., & Jayne, D. R. W. (2014) · Rheumatology · doi:10.1093/rheumatology/keu452 · Cited by 159
Self-citationKey advances in the clinical approach to ANCA-associated vasculitis
Kallenberg, C. G. M. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.104 · Cited by 145
Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis
van Daalen, E. E., Rizzo, R., Kronbichler, A., Wolterbeek, R., Bruijn, J. A., Jayne, D. R. W., Bajema, I. M., & Rahmattulla, C. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209925 · Cited by 147
Self-citationANCA-associated Vasculitis: Diagnostic Therapeutic Strategy
Ozaki, S. (2007) · Allergology International · doi:10.2332/allergolint.r-07-141 · Cited by 143
Immunopathogenesis of ANCA-Associated Vasculitis
Kronbichler, A., Lee, K. H., Denicolò, S., Choi, D., Lee, H., Ahn, D., Kim, K. H., Lee, J. H., Kim, H., Hwang, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197319 · Cited by 164
Hazebroek, M. R., Kemna, M. J., Schalla, S. M., Wijk, S. S., Gerretsen, S. C., Dennert, R. M., Merken, J. J., Kuznetsova, T., Staessen, J. A., Rocca, H. B., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.06.087 · Cited by 153
Self-citationRhee, R. L., Hogan, S. L., Poulton, C. J., Mcgregor, J., Landis, J. R., Falk, R. J., & Merkel, P. A. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39614 · Cited by 138
Smith, R., Jones, R. B., Specks, U., Bond, S. J., Nodale, M., Al-Jayyousi, R., Andrews, J., Bruchfeld, A. N., Camilleri, B., Carette, S., et al. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223559 · Cited by 136
Self-citationPuéchal, X., Pagnoux, C., Perrodeau, É., Hamidou, M. A., Boffa, J., Kyndt, X., Lifermann, F., Papo, T., Merrien, D., Smaïl, A., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39450 · Cited by 135
“The development of a 2-staged approach, with use of CYC initially (10) and use of rituximab thereafter (11,12) for induction of remission, followed by a less toxic remission-maintenance regimen to limit cumulative CYC exposure, was a major step forward in the treatment of GPA and MPA.”
MethodIdiopathic Membranous Nephropathy: Outline and Rationale of a Treatment Strategy
du Buf-Vereijken, P. W. G., Branten, A. J. W., & Wetzels, J. F. M. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.08.020 · Cited by 135
Anti-Glomerular Basement Membrane Disease
Cui, Z., Zhao, J., Jia, X., Zhu, S., Jin, Q., Cheng, X.-Y., & Zhao, M. (2011) · Medicine · doi:10.1097/md.0b013e31822f6f68 · Cited by 134
“The renal outcome of Wdouble positiveW patients was similar to that of anti-GBM disease, but worse than ANCAassociated vasculitis.(19) This finding is consistent with previous reports by us and by others.”
ResultBrown, K. M. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200511-120jh · Cited by 157
“In this study, that meant that the transition to maintenance therapy occurred generally within 3 to 6 mo, with no increase in the rate of relapse, disease activity score, or change in renal function (77).”
BackgroundChurg–Strauss syndrome: evidence for disease subtypes?
Pagnoux, C., & Guillevin, L. (2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328333390b · Cited by 143
Meggitt, S. J., Anstey, A. V., Mustapa, M. F. M., Reynolds, N. J., Wakelin, S. H., Tidman, M. J., Fuller, L. C., McLelland, J., Lear, J. T., Hughes, J. R., et al. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10575.x · Cited by 133
Szpirt, W. M., Heaf, J. G., & Petersen, J. H. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq360 · Cited by 130
Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease
Mcgregor, J., Hogan, S. L., Hu, Y., Jennette, C. E., Falk, R. J., & Nachman, P. H. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05610611 · Cited by 130
Weersma, R. K., Peters, F. T., Oostenbrug, L. E., van den Berg, A. P., van Haastert, M., Ploeg, R. J., Posthumus, M. D., van der Heide, J. J. H., Jansen, P. L. M., & van Dullemen, H. M. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02197.x · Cited by 127
“18 Also, in a recent study with patients with vasculitis associated with antineutrophil cytoplasmic autoantibodies treated with azathioprine, pancreatitis is not mentioned as an adverse event.(19) In this study we evaluated the occurrence of azathioprine-induced acute pancreatitis in patients with Crohn’s disease and…”
BackgroundMiloslavsky, E. M., Specks, U., Merkel, P. A., Seo, P., Spiera, R., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., Clair, E. W. S., Tchao, N. K., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.38044 · Cited by 123
Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis
Tam, F. W. K. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh487 · Cited by 124
“Current treatment consists of immunosuppressive therapy which is often associated with significant side effects [1,2].”
BackgroundDiagnosis and management of ANCA associated vasculitis
Berden, A. E., Göçeroǧlu, A., Jayne, D. R. W., Luqmani, R. A., Rasmussen, N., BRUIJN, J. A., & Bajema, I. M. (2012) · BMJ · doi:10.1136/bmj.e26 · Cited by 121
Self-citationTreatment of idiopathic membranous nephropathy
Hofstra, J. M., Fervenza, F. C., & Wetzels, J. F. M. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.125 · Cited by 126
Falk, R. J., & Jennette, J. C. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009121238 · Cited by 120
Rituximab as Maintenance Therapy for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Rhee, E. P., Laliberte, K. A., & Niles, J. L. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08821209 · Cited by 120
Japan RPGN Registry Group, Kôyama, A., Yamagata, K., Makino, H., Arimura, Y., Wada, T., Nitta, K., Nihei, H., Muso, E., Taguma, Y., et al. (2009) · Clinical and Experimental Nephrology · doi:10.1007/s10157-009-0201-7 · Cited by 119
“For the treatment of active renal vasculitis, to avoid relapses, and to improve long-term renal outcomes, treatment with cyclophosphamide is one choice; however, prolonged immunosuppression with a safer immunosuppressive agent, such as azathioprine [27], mycophenolate mofetil [28], or mizoribine [29], should also be c…”
BackgroundA pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis
Joy, M. S., Hogan, S. L., Jennette, J. C., Falk, R. J., & Nachman, P. H. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi117 · Cited by 115
“ANCA-positive patients who achieve a complete remission within 6 months of therapy usually have cyclophosphamide discontinued with close patient follow-up with or without maintenance immunosuppression (with azathioprine, for example) [2].”
BackgroundThe OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis
Merkel, P. A., Aydın, S. Z., Boers, M., Di̇reskeneli̇, H., Herlyn, K., Seo, P., Suppiah, R., Tómasson, G., & Luqmani, R. A. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.110276 · Cited by 115
“…a marked increase in the number and quality of clinical trials in the idiopathic inflammatory vasculitides, especially the small-vessel vasculitides known as antineutrophil cytoplasmic autoantibody (ANCA)-associ- ated vasculitis [AAV; granulomatosis, with polyangiitis (Wegener’s)] 1,2,3,4,5,6,7 .”
BackgroundMethodResultInfluentialVasculitis: mechanisms involved and clinical manifestations
Guillevin, L., & Dörner, T. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2193 · Cited by 113
“This is in addition to background corticosteroid therapy [49].”
BackgroundUpdate on Diffuse Alveolar Hemorrhage and Pulmonary Vasculitis
Krause, M. L., Cartin‐Ceba, R., Specks, U., & Peikert, T. (2012) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2012.08.001 · Cited by 121
“In a landmark randomized controlled trial, maintenance therapy with AZA (2 mg/kg for 18 months) was demonstrated to be as effective as longterm CYC treatment.(47) MTX (25 mg weekly) has also been demonstrated to be effective as remission maintenance therapy for AAV, and a recent randomized trial showed its equal effic…”
Evaluation of a new algorithm in classification of systemic vasculitis
Liu, L.-J., Chen, M., Yu, F., Zhao, M.-H., & Wang, H.-Y. (2008) · Lara D. Veeken · doi:10.1093/rheumatology/ken079 · Cited by 112
ANCA-associated vasculitis with renal involvement
Binda, V., Moroni, G. L., & Messa, P. (2017) · Journal of Nephrology · doi:10.1007/s40620-017-0412-z · Cited by 118
“In the prospective CYCAZAREM trial, patients with GPA had a greater chance of relapse than patients with MPA [62].”
Anti-Neutrophil Cytoplasm-Associated Glomerulonephritis
Morgan, M. D., Harper, L., Williams, J. H., & Savage, C. O. S. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005080882 · Cited by 112
Antineutrophil Cytoplasmic Antibody-Associated Vasculitides and Respiratory Disease
Gómez-Puerta, J. A., Hernández‐Rodríguez, J., López‐Soto, A., & Bosch, X. (2009) · CHEST Journal · doi:10.1378/chest.08-3043 · Cited by 112
Suppiah, R., Hadden, R. D. M., Batra, R. N., Arden, N., Collins, M. P., Guillevin, L., Jayne, D. R. W., Luqmani, R. A., & on behalf of the European Vasculitis Study Group (2011) · Lara D. Veeken · doi:10.1093/rheumatology/ker266 · Cited by 111
Self-citationGenetic variants in ANCA-associated vasculitis: a meta-analysis
Rahmattulla, C., Mooyaart, A. L., van Hooven, D., Schoones, J. W., Bruijn, J. A., Dekkers, O. M., & Bajema, I. M. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207601 · Cited by 123
A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis
Suppiah, R., Mukhtyar, C. B., Floßmann, O., Alberici, F., Baslund, B., Batra, R. N., Brown, D., Holle, J. U., Hrušková, Z., Jayne, D. R. W., et al. (2010) · Lara D. Veeken · doi:10.1093/rheumatology/keq400 · Cited by 111
Self-citationSacri, A., Chambaraud, T., Ranchin, B., Florkin, B., See, H., Decramer, S., Flodrops, H., Ulinski, T., Allain‐Launay, E., Boyer, O., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv011 · Cited by 110
Biologic therapy in primary systemic vasculitis of the young
Eleftheriou, D., Melo, M., Marks, S. D., Tullus, K., Sills, J., Cleary, G., Doležalová, P., Özen, S., Pilkington, C., Woo, P., et al. (2009) · Lara D. Veeken · doi:10.1093/rheumatology/kep148 · Cited by 110
Comparison of Phenotype and Outcome in Microscopic Polyangiitis Between Europe and Japan
Furuta, S., Chaudhry, A., Hamano, Y., Fujimoto, S., Nagafuchi, H., Makino, H., Matsuo, S., Ozaki, S., Endo, T., Muso, E., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130602 · Cited by 107
Self-citationFrequency, risk factors and prophylaxis of infection in ANCA ‐associated vasculitis
Kronbichler, A., Jayne, D. R. W., & Mayer, G. J. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12410 · Cited by 105
Self-citationPero, M. M. D., Chaudhry, A., Jones, R. B., Sivasothy, P. R., Jani, P., & Jayne, D. R. W. (2009) · Clinical Otolaryngology · doi:10.1111/j.1749-4486.2009.01968.x · Cited by 107
Self-citationClinical Manifestations and Treatment of Churg-Strauss Syndrome
Baldini, C., Talarico, R., Rossa, A. D., & Bombardieri, S. (2010) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2010.05.003 · Cited by 117
Silva, F., Specks, U., Kalra, S., Hogan, M. C., Leung, N., Sethi, S. M., & Fervenza, F. C. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06010809 · Cited by 103
“Because WG is more likely to relapse than MPA, it is not unexpected that the reported relapse rates of those cohorts were higher than observed in our trial (8,17,18).”
BackgroundResultInfluentialPrimary angiitis of the central nervous system: emerging variants
MacLaren, K., Gillespie, J. E., Shrestha, S., Neary, D., & BALLARDIE, F. W. (2005) · QJM · doi:10.1093/qjmed/hci098 · Cited by 103
Pepper, R. J., McAdoo, S. P., Moran, S. M., Kelly, D., Scott, J., Hamour, S., Burns, A. P., Griffith, M. E., Galliford, J. W., Levy, J. B., et al. (2018) · Rheumatology · doi:10.1093/rheumatology/key288 · Cited by 113
Self-citationEnd-stage renal disease in ANCA-associated vasculitis
Moiseev, S. V., Novikov, P. I., Jayne, D. R. W., & Mukhin, N. A. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw046 · Cited by 101
“The efficacy of such an approach as an alternative to prolonged cyclophosphamide administration was established in the CYCAZAREM study in 155 randomized patients [22].”
Self-citationHerpes zoster in immunocompromised patients: Incidence, timing, and risk factors
Wung, P. K., Holbrook, J. T., Hoffman, G. S., Tibbs, A. K., Specks, U., Min, Y., Merkel, P. A., Spiera, R., Davis, J. C., Clair, E. W. S., et al. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.06.012 · Cited by 100
ANCA-associated vasculitis in childhood: recent advances
Calatroni, M., Oliva, E., Gianfreda, D., Gregorini, G. A., Allinovi, M., Ramirez, G. A., Bozzolo, E. P., Monti, S. M., Bracaglia, C., Marucci, G., et al. (2017) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-017-0364-x · Cited by 97
“For remission-induction of organ- or life-threatening AAV in adults, the EULAR-ERA EDTA recommendations indicate treatment with a combination of glucocorticoids and either CYC or rituximab [44].”
ResultInfluentialSelf-citationMycophenolate Mofetil in Anti-Neutrophil Cytoplasm Antibodies-Associated Systemic Vasculitis
Koukoulaki, M., & Jayne, D. R. W. (2005) · Nephron Clinical Practice · doi:10.1159/000089667 · Cited by 97
Self-citationJayne, D. R. W. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.03.001 · Cited by 95
Self-citationCutaneous Manifestations of ANCA-Associated Small Vessels Vasculitis
Marzano, A. V., Raimondo, M. G., Berti, E., Meroni, P. L., & Ingegnoli, F. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8616-5 · Cited by 94
Management of ANCA associated vasculitis
Wallace, Z. S., & Miloslavsky, E. M. (2020) · BMJ · doi:10.1136/bmj.m421 · Cited by 94
Central Nervous System Vasculitis: Still More Questions than Answers
Alba, M. A., Espígol‐Frigolé, G., Prieto‐González, S., Tavera-Bahillo, I., García‐Martínez, A., Butjosa, M., Hernández‐Rodríguez, J., & Cid, M. C. (2011) · Current Neuropharmacology · doi:10.2174/157015911796557920 · Cited by 116
“By analogy to severe systemic vasculitis, switch to a safer immunosuppressive agent (azathioprine, methotrexate or mycophenolate) may be considered after 4-6 months of cyclophosphamide treatment [40-43].”
BackgroundCórdova‐Sánchez, B. M., Mejia-Vilet, J. M., Morales-Buenrostro, L. E., Loyola-Rodríguez, G., Uribe‐Uribe, N., & Correa‐Rotter, R. (2016) · Clinical Rheumatology · doi:10.1007/s10067-016-3195-z · Cited by 92
Tervaert, J. W. C., & Damoiseaux, J. G. M. C. (2012) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-012-8320-4 · Cited by 99
“After induction therapy with cyclophosphamide, azathioprine maintenance therapy is started [76].”
MethodSelf-citationHistopathologic and Clinical Predictors of Kidney Outcomes in ANCA-Associated Vasculitis
Ford, S. L., Polkinghorne, K. R., Longano, A., Dowling, J. P., Dayan, S., Kerr, P. G., Holdsworth, S. R., Kitching, A. R., & Summers, S. A. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.08.025 · Cited by 90
Nozu, T., Kondo, M., Suzuki, K. T., Tamaoki, J., & Nagai, A. (2008) · Respiration · doi:10.1159/000183754 · Cited by 94
Peripheral neuropathy in systemic vasculitides
Pagnoux, C., & Guillevin, L. (2004) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000145518.91595.2f · Cited by 88
Management of Acute Renal Failure in the Elderly Patient
Cheung, C. M., Ponnusamy, A., & Anderton, J. G. (2008) · Drugs & Aging · doi:10.2165/00002512-200825060-00002 · Cited by 98
Diffuse Alveolar Haemorrhage in ANCA-associated Vasculitis
West, S., Arulkumaran, N., Ind, P. W., & Pusey, C. D. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.8863 · Cited by 91
Self-citationBench-to-bedside review: Pulmonary–renal syndromes – an update for the intensivist
Papiris, S. A., Manali, E. D., Kalomenidis, I., Kapotsis, G. E., Karakatsani, A., & Roussos, C. (2007) · Critical Care · doi:10.1186/cc5778 · Cited by 86
“Transition to maintenance therapy may occur 6–12 months after the initiation of induction therapy or after clinical remission [101].”
BackgroundAn update on the classification and treatment of vasculitic neuropathy
Schaublin, G. A., Michet, C. J., Dyck, P. J. B., & Burns, T. M. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70249-0 · Cited by 88
Deoxyspergualin in relapsing and refractory Wegener's granulomatosis
Floßmann, O., Baslund, B., Bruchfeld, A. N., Tervaert, J.-W. C., Hall, C., Heinzel, P. A., Hellmich, B., Luqmani, R. A., Nemoto, K., Tesař, V., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092429 · Cited by 84
Self-citationS1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden
Schirmer, J. H., Aries, P. M., de Groot, K., Hellmich, B., Holle, J. U., Kneitz, C., Kötter, I., Lamprecht, P., Müller‐Ladner, U., Reinhold‐Keller, E., et al. (2017) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-017-0394-1 · Cited by 91
Maritati, F., Alberici, F., Oliva, E., Urban, M. L., Palmisano, A., Santarsia, F., Andrulli, S., Pavone, L., Pesci, A., Grasselli, C., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185880 · Cited by 87
Kahn, J., Blétry, O., & Guillevin, L. (2008) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2008.09.010 · Cited by 82
Bontscho, J., Schreiber, A., Manz, R. A., Schneider, W., Luft, F. C., & Kettritz, R. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010010034 · Cited by 81
Baughman, R. P., Meyer, K. C., Nathanson, I. T., Angel, L. F., Bhorade, S. M., Chan, K. M., Culver, D. A., Harrod, C. G., Hayney, M. S., Highland, K. B., et al. (2012) · CHEST Journal · doi:10.1378/chest.12-1044 · Cited by 86
Clinical Manifestations and Treatment of Wegener's Granulomatosis
Holle, J. U., Laudien, M., & Gross, W. L. (2010) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2010.05.008 · Cited by 80
Self-citationDhaun, N., Chariyavilaskul, P., MacIntyre, I. M., Muilwijk, E. W., Johnston, N. R., Kluth, D., Webb, D. J., & Goddard, J. G. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90713.2008 · Cited by 80
“Current treatments for inflammatory CKD include immunosuppressive therapy, which is often associated with significant side effects (18).”
BackgroundLai, Q., Ma, T., Li, Z., Chang, D., Zhao, M., & Chen, M. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.131426 · Cited by 80
Management of Lupus Nephritis: An Update
Houssiau, F. A. A. A. A. A. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000140218.77174.0a · Cited by 90
Mortality in Wegener's granulomatosis: a bimodal pattern
Luqmani, R. A., Suppiah, R., Edwards, C. J., Phillip, R., Maskell, J., Culliford, D. J., Jayne, D. R. W., Morishita, K. A., & Arden, N. (2010) · Lara D. Veeken · doi:10.1093/rheumatology/keq351 · Cited by 80
Self-citationHarigai, M., Nagasaka, K., Amano, K., Bando, M., Dobashi, H., Kawakami, T., Kishibe, K., Murakawa, Y., Usui, J., Wada, T., et al. (2018) · Modern Rheumatology · doi:10.1080/14397595.2018.1500437 · Cited by 79
“Considering the decreased risk when replacing CY with AZA, the CPG panel decided that the desirable consequence GCþAZA over GCþCY would probably outweigh the undesirable consequences and that the benefit of AZA outweighs its harm.”
BackgroundInfluentialLaurino, S., Chaudhry, A., Booth, A., Conte, G., & Jayne, D. R. W. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq187 · Cited by 79
Self-citationNachman, P. H., Jennette, J. C., & Falk, R. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10031-4 · Cited by 83
Naddaf, E., & Dyck, P. J. B. (2015) · Current Treatment Options in Neurology · doi:10.1007/s11940-015-0374-1 · Cited by 80
de Menthon, M., Cohen, P., Pagnoux, C., Büchler, M., Sibilia, J., Détrée, F., Gayraud, M., Khellaf, M., Penalba, C., Legallicier, B., et al. (2011) · PubMed · Cited by 78
Gorson, K. C. (2007) · The Neurologist · doi:10.1097/01.nrl.0000252942.14928.17 · Cited by 78
Pulmonary involvement in microscopic polyangiitis
Collins, C. E., & Quismorio, F. P. (2005) · Current Opinion in Pulmonary Medicine · doi:10.1097/01.mcp.0000170520.63874.fb · Cited by 78
“Jayne et al. [ 36 ] addressed this concern in a large prospective study investigating whether exposure to cyclophosphamide in patients with ANCA-associated vasculitis (60 of whom had MPA) could be reduced by the substitution of azathioprine at remission.”
BackgroundWalsh, M. W., Mukhtyar, C. B., Mahr, A., Herlyn, K., Luqmani, R. A., Merkel, P. A., & Jayne, D. R. W. (2011) · Arthritis Care & Research · doi:10.1002/acr.20471 · Cited by 81
Self-citation
Metadata
- Authors
- Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., Gross, W., Hagen, E. C., Mirapeix, E., Pettersson, E., Siegert, C., Sinico, A., Tesar, V., Westman, K., & Pusey, C.
- Affiliations
- Addenbrooke's Hospital (GB)
- Rigshospitalet (DK)
- University of Birmingham (GB)
- Maastricht University (NL)
- University of Helsinki (FI)
- Imperial College London (GB)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- University of Lübeck (DE)
- Hospital Clínic de Barcelona (ES)
- Leiden University Medical Center (NL)
- Azienda Ospedaliera Ospedale San Carlo Borromeo (IT)
- Lund University (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-07-03
- Volume
- 349
- Issue
- 1
- Pages
- 36-44
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1981535363
- Cited by
- 1,348
- References
- 44
- Citations by year
- 2026: 6 · 2025: 22 · 2024: 24 · 2023: 37 · 2022: 48 · 2021: 36 · 2020: 51 · 2019: 46 · 2018: 51 · 2017: 46 · 2016: 51 · 2015: 80 · 2014: 77 · 2013: 80 · 2012: 83
- FWCI
- 48.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Keywords
- ANCA-associated vasculitis, maintenance therapy, cyclophosphamide, azathioprine, granulomatosis with polyangiitis, microscopic polyangiitis, relapse, remission, prednisolone, adverse events
- MeSH terms
- Adult, Aged, Azathioprine, Cyclophosphamide, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunosuppressive Agents, Male, Middle Aged, Neutropenia, Prednisolone, Recurrence, Remission Induction, Vasculitis, Antibodies, Antineutrophil Cytoplasmic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.